First In-vivo Human Magnetic Particle Imaging
RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · 07.05.2026
DOI: 10.1055/a-2856-9878 ↗Kurz gefasst
Fachartikel in der Zeitschrift RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, online erschienen am 07.05.2026. Verfasst von Patrick Vogel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Julius-Maximilians University, Department of Experimental Physics 5 (Biophysics), Germany, Würzburg. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayerische Staatsministerium für Wirtschaft, Landesentwicklung und Energie, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Magnetic particle imaging (MPI) is a tracer-based imaging modality enabling radiation-free visualization of superparamagnetic iron oxide nanoparticles with high temporal resolution. Despite extensive preclinical development, in-vivo application in humans has not previously been reported so far. This study aimed to demonstrate the feasibility of first-in-human MPI angiography and to compare it with conventional X-ray digital subtraction angiography (DSA). A first-in-human MPI angiography was performed in a healthy volunteer using a human-scale interventional MPI scanner and clinically approved ferucarbotran tracer. Imaging of the upper extremity veins was conducted under clinical angiography laboratory conditions with continuous physiological monitoring. Conventional DSA of the same region was performed under identical procedural conditions for direct comparison. MPI data were acquired in real time with 2 frames per second and co-registered with DSA images. MPI successfully visualized major superficial and deep veins, including inflow, branching patterns, venous valve filling, collateral pathways, and tracer clearance dynamics. Spatial and temporal visualization was comparable to DSA for clinically relevant vascular structures. No adverse events occurred, and safety monitoring remained unremarkable throughout the procedure. This first in-vivo human demonstration shows that MPI enables real-time, radiation-free angiographic visualization of vascular structures with clinically relevant temporal resolution. MPI has potential as a novel imaging modality for selected vascular and interventional applications and represents an important step toward clinical translation.
Autor:innen und Institutionen
- Julius-Maximilians University, Department of Experimental Physics 5 (Biophysics), Germany, Würzburg.
- phase VISION GmbH, Germany, Rimpar.
- University Hospital, Department of Diagnostic and Interventional Neuroradiology, Germany, Würzburg.
- University Hospital, Department of Diagnostic and Interventional Radiology, Germany, Würzburg.
ORCID-Profile: Patrick Vogel, Thomas Kampf, Martin Andreas Rückert, Johanna Günther, Teresa Reichl, Thorsten Bley, Volker C Behr, Philipp Gruschwitz, Viktor Hartung
Förderung
- Bayerische Staatsministerium für Wirtschaft, Landesentwicklung und Energie
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Vogel, P., Kampf, T., Rückert, M. A., Günther, J., Reichl, T., Bley, T., Behr, V. C., Gruschwitz, P., & Hartung, V. (2026). First In-vivo Human Magnetic Particle Imaging. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. https://doi.org/10.1055/a-2856-9878
Vancouver
Vogel P, Kampf T, Rückert MA, Günther J, Reichl T, Bley T, et al. First In-vivo Human Magnetic Particle Imaging. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 2026. doi:10.1055/a-2856-9878
BibTeX
@article{Vogel2026,
author = {Vogel, Patrick and Kampf, Thomas and Rückert, Martin Andreas and Günther, Johanna and Reichl, Teresa and Bley, Thorsten and Behr, Volker C and Gruschwitz, Philipp and Hartung, Viktor},
title = {First In-vivo Human Magnetic Particle Imaging},
journal = {RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren},
year = {2026},
doi = {10.1055/a-2856-9878}
}
EUVIMED